HilleVax, Inc.

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2025 BST			5-day change	1st Jan Change
1.850 ^USD	-0.54%		-9.31%	-10.63%

05-08	HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
03-28	HilleVax, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI

Recursion Names HilleVax CEO Robert Hershberg as New Board Chair

Published on 24/05/2024 at 21:51, updated on 24/05/2024 at 21:58

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about HilleVax, Inc.

HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-08	CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	03-28	CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	03-28	CI
HilleVax, Inc. Announces Management Changes	12-05	CI
HilleVax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
HilleVax, Inc.(NasdaqGS:HLVX) dropped from S&P Global BMI Index	22/09/24	CI
HilleVax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	09/08/24	CI
Hillevax Announces Reduction in Force	31/07/24	CI
HilleVax, Inc. Announces Repay of Full the Entire $26.2 Million of Outstanding Principal and Interest Under Its Loan and Security Agreement	23/07/24	CI
JPMorgan Downgrades HilleVax to Neutral From Overweight, Cuts Price Target to $5 From $24	09/07/24	MT
Guggenheim Downgrades HilleVax to Neutral From Buy,	09/07/24	MT
Stifel Downgrades HilleVax to Hold From Buy, Adjusts Price Target to $3 From $34	09/07/24	MT
HC Wainwright Downgrades HilleVax to Neutral From Buy, Adjusts Price Target to $2 From $28	09/07/24	MT
Leerink Partners Downgrades HilleVax to Market Perform From Outperform, Adjusts Price Target to $2 From $28	09/07/24	MT
US Equities Markets End Mixed as Investors Await Inflation Data	08/07/24	MT
Sector Update: Health Care Stocks Softer Late Afternoon	08/07/24	MT
Sector Update: Health Care	08/07/24	MT
Top Midday Decliners	08/07/24	MT
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	08/07/24	RE
HilleVax shares plummet after norovirus vaccine fails in mid-stage study	08/07/24	RE
HilleVax's Acute Gastroenteritis Vaccines Fails Main Goal in Phase 2 Study; Shares Plunge Premarket	08/07/24	MT
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants	08/07/24	CI
Recursion Names HilleVax CEO Robert Hershberg as New Board Chair	24/05/24	MT
Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing	22/05/24	MT
HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05/24	CI

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Employees

Sector

Biotechnology & Medical Research

Calendar

06-23 - Annual General Meeting

More about the company